Nuritas announce peer reviewed publication of world’s first AI discovered anti-inflammatory
Nuritas, the world leader in artificial intelligence-based natural molecule discovery, has published an independent peer reviewed scientific paper in Foods Journal. The paper outlines the discovery of natural rice-based peptides clinically proven to impact inflammation and improve physical test results in an elderly population.
Whilst these peptides are found within food, critically, their health benefit cannot be achieved by simply eating rice. Nuritas’ unique approach is able to identify these previously undiscovered peptide molecules amongst the billions of peptides in rice and then unlock their biological functionality. The ensuing natural products that Nuritas creates have the capability to prevent the development of lifestyle and metabolic disease.
The paper entitled “An artificial intelligence characterised functional ingredient derived from rice inhibits TNF-α and significantly improves physical strength in an inflammaging population” describes the process of peptide discovery using AI, followed by laboratory based testing and carrying out a human clinical trial. Exciting data from this trial shows that significant reductions in TNF-α (an inflammatory cytokine) in the blood corresponds with significant improvements in a number of standardised physical tests. These physical tests can be useful predictors of the likelihood of future falls, for example.
Discovered using our proprietary ground-breaking AI technology NπΦ (pronounced N-pi-fy or Nuritas Peptide Finder), the new natural rice product shows huge potential to improve the health of the globally ageing population. “Inflammaging” – the term used for age related chronic inflammation, increases the risk of a multitude of health conditions including muscle wastage, strength loss and general immunity.
“The results or the trial couldn’t come at a more significant time. With COVID-19 heightening general awareness of inflammation and cytokines, discovering a natural product which can assist is a hugely significant finding for the team. This is as a result of years of hard work refining our AI and machine learning platform in combination with our expert in-house laboratory and team of world class scientific advisors” commented Dr Nora Khaldi, Nuritas Founder and CEO.
Neil Foster, head of strategic partnerships at Nuritas said, “2020 is looking to be a seminal year in the way that consumers value and are taking responsibility for their health. Consumers are also becoming far more discerning, they want natural but also the latest science and efficacy that can be measured or better still felt.” Foster added, “Against this backdrop Nuritas is launching three new products, had multiple papers published with some incredible clinical results. The interest and appetite for the Nuritas offering of fully characterised natural products that work is incredible”.
This is the latest in a series of peer reviewed papers recently published from Nuritas discoveries including the first clinically tested AI discovered anti-aging molecule PeptiYouthTM, as well as PeptiStrongTM, a product addressing muscle wasting., all important health areas needing new solutions.
-
Most popular related searches
Related news
-
Sysmex Continues to Evolve Its Hematology Product Portfolio
Since its founding in 1968, Sysmex has developed its business by focusing on the hematology field (blood cell count tests), which analyzes the number, type, and size of red and white blood cells as well as platelets. Sysmex has adopted a modular concept since the launch of the XN-Series Automated Hematology Analyzer (“XN-Series”) in 2011, combining modules for blood count, smear preparation, automated digital cell morphology analysis and sample sorting to offer a broad range of system options tailored...
-
INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18
INOVIO, (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, today announced it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial. This trial is one of two ongoing pivotal, randomized, double-blind, multi-center, placebo-controlled, Phase 3 trials (REVEAL 1 and REVEAL 2) evaluating the safety, tolerability and efficacy of VGX-3100 to treat...
-
Inflammatix Announces $7.4 Million in Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test
Inflammatix a pioneering molecular diagnostics company, announced today a contract extension of $7.4 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, to further develop its point-of-care test and system to diagnose infection by reading the immune system. The contract is part of a BARDA contract worth up to $72 million, if all options are exercised. The...
-
Thermo Fisher Scientific Introduces Oncomine Clinical Research Grant Program to Support Oncology and Reproductive Health Studies
Thermo Fisher Scientific today introduced the Oncomine Clinical Research Grant Program to support clinical research projects in oncology and reproductive health. The program aims to provide support for high-quality molecular profiling studies focused on the generation of data that may improve clinical outcomes for patients in the future. As part of an initial pilot focused on oncology, the company is calling for proposals dedicated to gene fusions in solid tumors and molecular testing in blood cancers. Grant...
-
Thermo Fisher Scientific Announces Collaborations to Meet Unmet Clinical Needs in Biomarker Discovery and Characterization
Thermo Fisher Scientific, the world leader in serving science, today announced new collaborations of the Thermo Fisher Precision Medicine Science Center (PMSC) with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of innovative solutions for unmet needs in clinical biomarker discovery. The new alliances strengthen the PMSC`s mission of creating standardized workflows with pharma and academic partners to streamline the transition from biomarker research to clinical...
Customer comments
No comments were found for Nuritas announce peer reviewed publication of world’s first AI discovered anti-inflammatory. Be the first to comment!